SI20008B - Improved meningococcal polysaccharide conjugate vaccine - Google Patents

Improved meningococcal polysaccharide conjugate vaccine Download PDF

Info

Publication number
SI20008B
SI20008B SI9110243A SI9110243A SI20008B SI 20008 B SI20008 B SI 20008B SI 9110243 A SI9110243 A SI 9110243A SI 9110243 A SI9110243 A SI 9110243A SI 20008 B SI20008 B SI 20008B
Authority
SI
Slovenia
Prior art keywords
group
butanoyl
polysaccharide
pentanoyl
modified polysaccharide
Prior art date
Application number
SI9110243A
Other languages
English (en)
Other versions
SI20008A (sl
Inventor
Harold J Jennings
Francis Michon
Original Assignee
Ca Nat Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ca Nat Research Council filed Critical Ca Nat Research Council
Publication of SI20008A publication Critical patent/SI20008A/sl
Publication of SI20008B publication Critical patent/SI20008B/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Claims (16)

  1. Λ IZBOLJŠANO MENINGOKOKALNO POLISAHARIDNO KONJUGIRANO CEPIVO PATENTNI ZAHTEVKI 1. Modificirani polisaharid skupine B Neisseria Meningitidis, značilen po tem, da ima ostanek sialinske kisline N-acetilnih skupin naravnega polisaharida nadomeščene s C4-C8-acilnimi skupinami, kjer ima modificirani polisaharid povprečno molekulsko maso v obsegu 10.000 do 50.000 Daltonov.
  2. 2. Modificirani polisaharid KI iz ovojnice E. coli, značilen po tem, da ima ostanek sialinske kisline iz N-acetilnih skupin naravnega polisaharida nadomeščene s C4-C8 acilnimi skupinami, kjer ima modificirani polisaharid povprečno molekulsko maso v obsegu 10.000 do 50.000 Daltonov.
  3. 3. Modificiran polisaharid po zahtevku 1 , značilen po tem, da je C4-C8 acilna skupina izbrana iz skupine, ki jo sestavljajo n-butanoil, izobutanoil, n-pentanoil, n-heksanoil, n-heptanoil in n-oktanoil.
  4. 4.Modificirani polisaharid po zahtevku 3, značilen po tem, da je acilna skupina izbrana iz skupine, ki jo sestavljajo n-butanoil, izo-butanoil, n-pentanoil in n- heksanoil. 2 ^ · Modificiran polisaharid po zahtevku 2 , značilen po tem, da je C4-C8 skupina izbrana iz skupine, ki jo sestavljajo n-butanoil, izo-butanoil, n-pentanoil, n-heksanoil, n-heptanoil in n-oktanoil.
  5. 6.Modificirani polisaharid po zahtevku 5, značilen po tem, da je acilna skupina izbrana iz skupine, ki jo sestavljajo n-butanoil, izo-butanoil, n-pentanoil in n-heksanoil. 1 - Polisaharid po zahtevku 1, značilen po tem, da je od 90% do 100% ostanka slatinske kisline N-acetilnih skupin nadomeščeno s C^-Cg-acilnimi skupinami.
  6. 8. Polisaharid po zahtevku 2, značilen po tem, da je od 90% do 100% ostanka sialinske kisline N-acetilnih skupin nadomeščeno s C4-Ce-acilnimi skupinami.
  7. 9. Antigenski konjugat, značilen po tem, da obsega modificirano skupino polisaharida B Neisseria meningitidis, ki ima ostanek sialinske kisline N-acetilne skupine nadomeščen z N-C^-Cg-acilno skupino, konjugiran na imunološko primeren protein, kjer ima modificirani polisaharid povprečno molekulsko maso v obsegu 10.000 do 50.000 Daltonov.
  8. 10. Konjugat po zahtevku 9, značilen po tem, da je acilna skupina izbrana iz skupine, ki jo sestavljajo n-butanoil, izo-butanoil, n-pentanoil, izo-pentanoil, neo-pentanoil, heksanoil, heptanoil in oktanoil.
  9. 11. Konjugat po zahtevku 10, značilen po tem, da je acilna skupina izbrana iz skupine, ki jo sestavljajo n-butanoil, izo-butanoil, n-pentanoil in heksanoil. 3
  10. 12. Konjugat po zahtevku 9, značilen po tem, da je protein izbran iz skupine, ki jo sestavljajo tetanusni toksoid, difteria toksoid, navzkrižno reaktivni material (CRM) in bakterijski proteinski nosilec.
  11. 13. Konjugat po zahtevku 9, značilen po tem, da sta protein in polisaharid povezana kovalentno z vezjo -CH2-NH-protein.
  12. 14. Konjugat po zahtevku 12, značilen po tem, da je CRM CRM197.
  13. 15. Cepivo, značilno po tem, da obsega konjugat po zahtevku 9 in farmacevtsko sprejemljiv injekcijski nosilec.
  14. 16. Cepivo po zahtevku 15, značilno po tem, da nadalje obsega tudi fiziološko sprejemljiv adjuvant.
  15. 17. Cepivo po zahtevku 16, značilno po tem, da je omenjeni adjuvant izbran iz skupine, ki jo sestavljajo aluminijev hidroksid, aluminijev fosfat in aluminijev sulfat.
  16. 18. Gama globulinska frakcija, značilna po tem, da je sposobna pasivno zaščititi proti meningitisu, ki ga povzroča skupina B N. meningitidis in E. coli KI, omenjeno frakcijo pa pridobivamo z imunizacijo sesalcev s cepivom, po zahtevku 17, nakar sledi izločaje gama globulina iz omenjenega sesalca.
SI9110243A 1989-12-14 1990-12-14 Improved meningococcal polysaccharide conjugate vaccine SI20008B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44819589A 1989-12-14 1989-12-14
YU24391A YU24391A (sh) 1989-12-14 1990-12-14 Poboljšana meningokokna polisaharid kon-jugovana vakcina

Publications (2)

Publication Number Publication Date
SI20008A SI20008A (sl) 2000-02-29
SI20008B true SI20008B (en) 2001-02-28

Family

ID=23779371

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9110243A SI20008B (en) 1989-12-14 1990-12-14 Improved meningococcal polysaccharide conjugate vaccine

Country Status (30)

Country Link
US (3) US5576002A (sl)
EP (1) EP0504202B1 (sl)
JP (1) JP2637845B2 (sl)
KR (1) KR0158436B1 (sl)
CN (4) CN1049223C (sl)
AR (1) AR243934A1 (sl)
AT (1) ATE121947T1 (sl)
AU (1) AU641715B2 (sl)
BR (1) BR9007917A (sl)
CA (1) CA2071811C (sl)
CZ (1) CZ283530B6 (sl)
DE (1) DE69019164T2 (sl)
DK (1) DK0504202T3 (sl)
ES (1) ES2071288T3 (sl)
FI (2) FI104539B (sl)
HR (1) HRP920872A2 (sl)
HU (2) HU9201966D0 (sl)
IE (1) IE68414B1 (sl)
IL (1) IL96676A (sl)
IN (1) IN171747B (sl)
NO (2) NO305275B1 (sl)
NZ (1) NZ236471A (sl)
PH (1) PH30305A (sl)
PL (2) PL166035B1 (sl)
RO (1) RO111416B1 (sl)
RU (1) RU2105568C1 (sl)
SI (1) SI20008B (sl)
WO (1) WO1991008772A1 (sl)
YU (1) YU24391A (sl)
ZA (1) ZA9010065B (sl)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648241A (en) 1989-09-15 1997-07-15 The General Hospital Corporation Conjugate vaccine against group B streptococcus
HU9201966D0 (en) * 1989-12-14 1992-10-28 Ca Nat Research Council An improved vaccine of meningococcus-polysaccharide conjunction
DK0667787T3 (da) * 1992-09-24 2001-10-29 Ca Nat Research Council Gruppe B-streptococcus type II- og type V-polysaccharid-protein-konjugat-vacciner
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US6153406A (en) * 1993-07-23 2000-11-28 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane protein P2 from Haemophilus influenzae type B
US5679654A (en) * 1994-09-02 1997-10-21 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5700787A (en) * 1994-09-02 1997-12-23 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5747287A (en) * 1995-04-28 1998-05-05 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US6284884B1 (en) 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
US5811102A (en) * 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
ATE400295T1 (de) * 1995-06-07 2008-07-15 Glaxosmithkline Biolog Sa Vakzine mit einem polysaccharide antigen- trägerprotein konjugat und freiem trägerprotein
ZA97248B (en) * 1996-01-18 1997-07-18 Rohm & Haas Method for identifying and quantifying polymers utilizing immunoassay techniques
EP0939647B2 (en) † 1996-08-27 2006-07-12 Chiron Corporation Neisseria meningitidis serogroup b glycoconjugates and methods of using the same
JP4150082B2 (ja) 1996-08-27 2008-09-17 カイロン コーポレイション 独特の髄膜炎菌性ｂエピトープを規定するモノクローナル抗体およびワクチン組成物の調製におけるそれらの使用
US6426074B1 (en) * 1997-03-19 2002-07-30 The Brigham And Women's Hospital Inc. Group B Streptococcus vaccine
WO1998058670A1 (en) 1997-06-24 1998-12-30 Chiron Corporation Methods of immunizing adults using anti-meningococcal vaccine compositions
EP1007546B1 (en) * 1997-08-27 2009-01-21 Novartis Vaccines and Diagnostics, Inc. Molecular mimetics of meningococcal b epitopes
CZ302615B6 (cs) 1997-12-23 2011-08-03 Baxter Healthcare S.A. Zpusob cištení kapsulárních polysacharidu od bunecných komponent gramnegativních a grampozitivních bakterií a modifikovaný kapsulární polysacharid
PL346645A1 (en) * 1998-08-19 2002-02-25 North American Vaccine IMMUNOGENIC β-PROPIONAMIDO-LINKED POLYSACCHARIDE PROTEIN CONJUGATE USEFUL AS A VACCINE PRODUCED USING AN N-ACRYLOYLATED POLYSACCHARIDE
CN1263510C (zh) * 1998-08-19 2006-07-12 巴克斯特健康护理股份有限公司 多糖－蛋白质缀合物或寡糖－蛋白质缀合物、其制备方法及其应用
US6436653B1 (en) 1998-12-15 2002-08-20 Exiqon A/S Method for introduction of reporter groups into bacterial lipopolysaccharide-derived carbohydrates and the subsequent coupling of such derivatives onto solid surfaces
US7083777B1 (en) * 1999-04-02 2006-08-01 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
US6518037B2 (en) * 1999-11-12 2003-02-11 University Of Iowa Research Foundation Two-component system that controls bacterial membrane synthesis
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
GB0011108D0 (en) * 2000-05-08 2000-06-28 Microscience Ltd Virulence gene and protein and their use
SV2003000753A (es) 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
US7534444B2 (en) 2001-04-17 2009-05-19 Novattis Vaccines And Diagnostics, Inc. Molecular mimetics of meningococcal B epitopes which elicit functionally active antibodies
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0121591D0 (en) * 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
CA2480389C (en) * 2002-03-26 2012-10-09 Chiron Srl Modified saccharides having improved stability in water
EP1506007B1 (en) * 2002-05-14 2011-06-22 Novartis Vaccines and Diagnostics S.r.l. Mucosal combination vaccines for bacterial meningitis
RU2317106C2 (ru) * 2002-08-02 2008-02-20 ГлаксоСмитКлайн Байолоджикалз с.а. Нейссериальные вакцинные композиции, содержащие комбинацию антигенов
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
AU2004227852B2 (en) * 2003-03-31 2010-01-14 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
US7807824B2 (en) 2003-08-12 2010-10-05 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
US8148335B2 (en) 2004-06-23 2012-04-03 Children's Hospital & Research Center Oakland De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
JP2008509886A (ja) * 2004-06-23 2008-04-03 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド 多糖誘導体および免疫応答の誘導における用途
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
KR20130122810A (ko) 2005-06-27 2013-11-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신 제조 방법
WO2007092451A2 (en) 2006-02-06 2007-08-16 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
GB0611914D0 (en) 2006-06-15 2006-07-26 Teti Giuseppe Peptides that mimic non-human cross-reactive protective epitopes of the group Bmeningococcal capsulsar polysaccharide
EP1872791A1 (en) * 2006-06-30 2008-01-02 Institut Pasteur Use of bacterial polysaccharides for biofilm inhibition
US20100189740A1 (en) * 2007-06-20 2010-07-29 Francis Michon Modified polysaccharides for conjugate vaccines
ES2664753T3 (es) 2007-12-07 2018-04-23 Glaxosmithkline Biologicals Sa Composiciones de inducción de respuestas inmunes
EP2387417B1 (en) 2009-01-16 2016-05-11 University of Maryland, Baltimore Broad spectrum vaccine against non-typhoidal salmonella
US9539281B2 (en) 2011-07-12 2017-01-10 The Brigham And Women's Hospital, Inc. Lipid-containing PSA compositions, methods of isolation and methods of use thereof
EP2752403A1 (de) * 2013-01-08 2014-07-09 Sika Technology AG Amin für emissionsarme Epoxidharz-Produkte
CA2997211A1 (en) 2015-08-19 2017-02-23 President And Fellows Of Harvard College Lipidated psa compositions and methods
WO2018014012A1 (en) 2016-07-15 2018-01-18 President And Fellows Of Harvard College Glycolipid compositions and methods of use
CN118021947A (zh) * 2017-01-31 2024-05-14 辉瑞大药厂 脑膜炎奈瑟菌组合物及其使用方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) * 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4496538A (en) * 1982-07-06 1985-01-29 Connaught Laboratories, Inc. Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
US4644059A (en) * 1982-07-06 1987-02-17 Connaught Laboratories, Inc. Haemophilus influenzae B polysaccharide-diptheria toxoid conjugate vaccine
US4619828A (en) * 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
HU9201966D0 (en) * 1989-12-14 1992-10-28 Ca Nat Research Council An improved vaccine of meningococcus-polysaccharide conjunction

Also Published As

Publication number Publication date
DE69019164T2 (de) 1995-09-07
CN1055541A (zh) 1991-10-23
CA2071811A1 (en) 1991-06-15
EP0504202B1 (en) 1995-05-03
NZ236471A (en) 1992-10-28
DE69019164D1 (de) 1995-06-08
IE904513A1 (en) 1991-06-19
DK0504202T3 (da) 1995-10-02
NO307835B1 (no) 2000-06-05
CN1100428A (zh) 1995-03-22
FI19991917A7 (fi) 1999-09-09
SI20008A (sl) 2000-02-29
ES2071288T3 (es) 1995-06-16
PH30305A (en) 1997-02-20
CZ283530B6 (cs) 1998-04-15
FI922737A0 (fi) 1992-06-12
PL288271A1 (en) 1991-12-16
RU2105568C1 (ru) 1998-02-27
FI104539B (fi) 2000-02-29
CN1096516A (zh) 1994-12-21
KR0158436B1 (ko) 1998-12-01
FI19991917L (fi) 1999-09-09
HRP920872A2 (en) 1997-06-30
AU6898791A (en) 1991-07-18
CN1036522C (zh) 1997-11-26
ZA9010065B (en) 1992-02-26
CN1036504C (zh) 1997-11-26
EP0504202A1 (en) 1992-09-23
HUT64480A (en) 1994-01-28
NO922316D0 (no) 1992-06-12
CA2071811C (en) 2003-11-04
IL96676A (en) 1996-09-12
NO973311L (no) 1992-08-14
US5683699A (en) 1997-11-04
CN1100656A (zh) 1995-03-29
NO305275B1 (no) 1999-05-03
BR9007917A (pt) 1992-10-20
IN171747B (sl) 1992-12-26
AU641715B2 (en) 1993-09-30
CN1072506C (zh) 2001-10-10
US5902586A (en) 1999-05-11
NO973311D0 (no) 1997-07-17
IL96676A0 (en) 1991-09-16
JP2637845B2 (ja) 1997-08-06
YU24391A (sh) 1995-12-04
ATE121947T1 (de) 1995-05-15
CZ628490A3 (en) 1997-12-17
US5576002A (en) 1996-11-19
WO1991008772A1 (en) 1991-06-27
NO922316L (no) 1992-08-14
PL166659B1 (pl) 1995-06-30
CN1049223C (zh) 2000-02-09
AR243934A1 (es) 1993-09-30
PL166035B1 (pl) 1995-03-31
RO111416B1 (ro) 1996-10-31
HU218146B (hu) 2000-06-28
JPH05505392A (ja) 1993-08-12
IE68414B1 (en) 1996-06-12
HU9201966D0 (en) 1992-10-28

Similar Documents

Publication Publication Date Title
SI20008B (en) Improved meningococcal polysaccharide conjugate vaccine
US6531131B1 (en) Conjugate vaccine for Neisseria meningitidis
KR100593466B1 (ko) 다당류-펩타이드접합체
EP0754055B1 (en) Group a streptococcal polysaccharide immunogenic compositions and methods
JP2004505885A5 (sl)
RU2009108660A (ru) Вакцины на основе солюбилизированных и комбинированных капсулярных полисахаридов
KR920003982A (ko) 면역원성 콘쥬게이트 및 이를 함유하는 백신 조성물
IL119962A0 (en) Process for making a pneumococcal polysaccharide-immunogenic protein conjugate
ATE19734T1 (de) Heamophilus influenzae b polysaccharid exotoxoid konjugat-impfstoff.
RU2006114677A (ru) Жидкие вакцины для множественных серогрупп менингококков
US5192540A (en) Haemophilus influenzae type b oxidized polysaccharide-outer membrane protein conjugate vaccine
LU90808I2 (fr) Conjugue serotype 18c d'oligosaccharide pneumococcique
DE68917126D1 (de) T-zellen-epitope als träger für einen konjugierten impfstoff.
LU91924I2 (fr) Composition vaccinale comprenant le polysaccharidecapsulaire et Haemophilus influenzae type b coupl é à l'anatoxine tétanique, l'antigène diphtérique,l'antigène tétanique, des antigènes de la polio, des antigènes de la coqueluche et du phosphate d'aluminium
ES2000140A6 (es) Procedimiento para preparar vacunas conjugadas no toxicas contra infecciones por bacterias gram-negativas
NZ299249A (en) Use of an antigenic conjugate of a capsular polysaccharide from streptococcus and a protein component to immunise neonates
EP0338265B1 (en) Haemophilus influenzae type B polysaccharide-outer membrane protein conjugate vaccine
US6165468A (en) Antigenic carbohydrate linked to an immunogenic carrier
RU2001107132A (ru) Иммуногенный конъюгат бета-пропионамид-связанного полисахарида с белком, использующийся в качестве вакцины, который получают с помощью n-акрилоилированного полисахарида
RU2023120100A (ru) Пневмококковые полисахариды и их применение в иммуногенных конъюгатах полисахарид-белок-носитель
Verheul et al. Immunogenicity of meningococcal LPS derived oligosaccharide-protein conjugates using isolated and synthetic oligosaccharides
MXPA98007617A (es) Conjugados de polisacaridos peptidos

Legal Events

Date Code Title Description
IF Valid on the event date
KO00 Lapse of patent

Effective date: 20090910